These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 29892172)

  • 1. Sofosbuvir Based Regimen in Management of Hepatitis C for Patients With End Stage Renal Disease on Hemodialysis: A Single Center Experience from India.
    Gupta A; Arora P; Jain P
    J Clin Exp Hepatol; 2018 Jun; 8(2):116-120. PubMed ID: 29892172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.
    Goel A; Bhargava R; Rai P; Aggarwal R
    Indian J Gastroenterol; 2017 May; 36(3):227-234. PubMed ID: 28656492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sofosbuvir and Velpatasvir Regimen Outcome for Chronic Hepatitis C Patients With End-Stage Renal Disease Undergoing Hemodialysis.
    Shahid S; Asghar S; Mahmood T; Fatima M; Rasheed A; Asghar S
    Cureus; 2023 Sep; 15(9):e45680. PubMed ID: 37868481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.
    Borgia SM; Dearden J; Yoshida EM; Shafran SD; Brown A; Ben-Ari Z; Cramp ME; Cooper C; Foxton M; Rodriguez CF; Esteban R; Hyland R; Lu S; Kirby BJ; Meng A; Markova S; Dvory-Sobol H; Osinusi AO; Bruck R; Ampuero J; Ryder SD; Agarwal K; Fox R; Shaw D; Haider S; Willems B; Lurie Y; Calleja JL; Gane EJ
    J Hepatol; 2019 Oct; 71(4):660-665. PubMed ID: 31195062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
    Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
    J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience.
    Naguib GG; Farid A; Hassan M; Elshafie A; Shazly YE; Shaker MK; Ezzat H; Safwat E; Ahmed OA; Dabbous H; Sherief AF; Hassany M; Elserafy M; Elsayed MH
    Arab J Gastroenterol; 2021 Dec; 22(4):285-291. PubMed ID: 34531135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease.
    Taneja S; Duseja A; De A; Mehta M; Ramachandran R; Kumar V; Kohli HS; Gupta KL; Dhiman RK; Chawla Y
    Dig Dis Sci; 2018 May; 63(5):1334-1340. PubMed ID: 29484572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03).
    Wehmeyer MH; Ingiliz P; Christensen S; Hueppe D; Lutz T; Simon KG; Schewe K; Boesecke C; Baumgarten A; Busch H; Rockstroh J; Schmutz G; Kimhofer T; Berger F; Mauss S; Schulze Zur Wiesch J
    J Med Virol; 2018 Feb; 90(2):304-312. PubMed ID: 28710853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.
    Abdelaty LN; Elnaggar AA; Said AA; Hussein RRS
    Curr Drug Saf; 2020; 15(1):53-60. PubMed ID: 31573893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
    Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
    Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
    Akhil MS; Kirushnan B; Martin M; Arumugam K; Ganesh Prasad NK; Ravichandran R
    Nephrology (Carlton); 2018 May; 23(5):446-452. PubMed ID: 28339162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C).
    Poordad F; Shiffman ML; Ghesquiere W; Wong A; Huhn GD; Wong F; Ramji A; Shafran SD; McPhee F; Yang R; Noviello S; Linaberry M;
    Antivir Ther; 2019; 24(1):35-44. PubMed ID: 30382942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
    Pol S; Bourliere M; Lucier S; Hezode C; Dorival C; Larrey D; Bronowicki JP; Ledinghen VD; Zoulim F; Tran A; Metivier S; Zarski JP; Samuel D; Guyader D; Marcellin P; Minello A; Alric L; Thabut D; Chazouilleres O; Riachi G; Bourcier V; Mathurin P; Loustaud-Ratti V; D'Alteroche L; Fouchard-Hubert I; Habersetzer F; Causse X; Geist C; Rosa I; Gournay J; Saillard E; Billaud E; Petrov-Sanchez V; Diallo A; Fontaine H; Carrat F;
    J Hepatol; 2017 Jan; 66(1):39-47. PubMed ID: 27622858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence.
    Llewellyn A; Faria R; Woods B; Simmonds M; Lomas J; Woolacott N; Griffin S
    Pharmacoeconomics; 2016 Oct; 34(10):981-92. PubMed ID: 27278217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
    Taneja S; Duseja A; De A; Kumar V; Ramachandran R; Sharma A; Dhiman RK; Gupta KL; Chawla Y
    Nephrology (Carlton); 2018 Sep; 23(9):876-882. PubMed ID: 28703905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection.
    Foster GR; Pianko S; Brown A; Forton D; Nahass RG; George J; Barnes E; Brainard DM; Massetto B; Lin M; Han B; McHutchison JG; Subramanian GM; Cooper C; Agarwal K;
    Gastroenterology; 2015 Nov; 149(6):1462-70. PubMed ID: 26248087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.
    Sulkowski MS; Feld JJ; Lawitz E; Felizarta F; Corregidor AM; Khalid O; Ghalib R; Smith WB; Van Eygen V; Luo D; Vijgen L; Gamil M; Kakuda TN; Ouwerkerk-Mahadevan S; Van Remoortere P; Beumont M
    J Viral Hepat; 2018 Jun; 25(6):631-639. PubMed ID: 29274193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
    García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
    Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real Life Egyptian Experience of Daclatasvir Plus Sofosbuvir with Ribavirin in Naïve Difficult to Treat HCV Patients.
    Wahsh EA; Hussein AK; Gomaa AA; Baraka MA; Al-Deen Abead M
    Infect Disord Drug Targets; 2020; 20(1):43-48. PubMed ID: 30009715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
    Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
    J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.